3 month semaglutide program (Any Dose) Fridays | GLP-1 Telehealth |

Long-acting, subcutaneously administered, PYY RA are undergoing early phase clinical trials as obesity treatments either alone or in combination with GLP-1 RA (Table 1, NCT02568306 and NCT03574584)

The FDA-approved maximum dose for weight loss (Wegovy) is 2.4 mg weekly, though clinical practice often caps therapeutic semaglutide at 1.0 to 2.0 mg weekly for compounded formulations

Cost comparison and accessibility Both weight loss drugs are similar in terms of price

Possible option of remote lab assessment if youre unable to make it in-person

TRIUMPH trials had no blanket exclusion, but may complicate treatment

To get detailed logistics and pricing information, reach out via the Inquire Now button or Sign Up for direct supplier interaction.